Welcome to our dedicated page for Summit Therapeutics news (Ticker: $SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Summit Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Summit Therapeutics's position in the market.
Rhea-AI Summary
Summit Therapeutics Inc. (NASDAQ: SMMT) will conduct an earnings call on February 20, 2024, to reveal its fourth quarter and full year 2023 financial results and provide an operational update. The call will be live-streamed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
News
Rhea-AI Summary
Summit Therapeutics Inc. (NASDAQ: SMMT) will present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference to discuss the development of their investigational bispecific antibody, ivonescimab. The presentation will be available live on their website and an archived version will be available afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
-
Rhea-AI Summary
Summit Therapeutics Inc. (NASDAQ: SMMT) announced promising developments in the Phase II trial of ivonescimab for NSCLC patients, with a 64.8% 24-month overall survival rate in 1L squamous NSCLC patients and a 22.5-month median overall survival in 2L+ EGFRm, TKI-progressed NSCLC patients. The company also revealed near-term catalyst events expected in Q2 2024 for two randomized Phase III trials evaluating ivonescimab in China, conducted by Akeso.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.47%
Tags
Rhea-AI Summary
Summit Therapeutics Inc. (NASDAQ: SMMT) announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 09, 2024. The company's Chairman and CEO, Robert W. Duggan, and Dr. Maky Zanganeh, CEO and President, will provide updates on the development of the investigational bispecific antibody, ivonescimab. The audio presentation will be available live and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
Summit Therapeutics Inc. (NASDAQ: SMMT) reports its financial results for the third quarter and nine months ended September 30, 2023. The company is actively engaged in developing ivonescimab (SMT112), an innovative bispecific antibody. Enrollment is expected to complete in the second half of 2024 for the Phase III HARMONi clinical trial, and the second Phase III clinical study, HARMONi-3, has commenced patient enrollment. Summit has also entered into a Collaboration and License Agreement with Akeso Inc. for ivonescimab, receiving the rights to develop and commercialize ivonescimab in specific territories in exchange for an upfront payment of $500 million. The company has bolstered its leadership team and clinical experience, with Manmeet S. Soni joining as COO and making a $5 million investment in the company. Financially, Summit has sufficient funds to operate into the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.16%
Tags
-
Rhea-AI Summary
Summit Therapeutics Inc. has announced that Dr. Laura Chow has joined the company as Senior Vice President of Clinical Development. Dr. Chow brings two decades of experience in immunotherapy and anti-angiogenic cancer treatment. She has worked on the development of immunotherapies for oncology patients and has extensive experience with major therapies in the field. Dr. Chow's expertise will be valuable in advancing Summit's novel bispecific antibody, ivonescimab, in lung cancer and other solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Rhea-AI Summary
Akeso announces that its partner, Summit Therapeutics, will present data for the potential first-in-class bispecific antibody, ivonescimab, at the SITC Annual Meeting. Ivonescimab combines immunotherapy via PD-1 blockade with anti-angiogenesis effects by blocking VEGF. It demonstrates enhanced binding in the presence of both PD-1 and VEGF, potentially targeting tumor tissue. The marketing application for ivonescimab was accepted in China with priority review. Four phase III clinical trials are underway, testing ivonescimab in NSCLC indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
-
Rhea-AI Summary
Summit Therapeutics Inc. announces data for its potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. Ivonescimab combines immunotherapy via a blockade of PD-1 with anti-angiogenesis effects associated with blocking VEGF. It demonstrates enhanced binding in the simultaneous presence of PD-1 and VEGF, with over 18 fold increased binding affinity to PD-1 in the presence of VEGF in vitro. Summit has begun clinical development to establish efficacy and safety in two proposed NSCLC indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
Summit Therapeutics Inc. will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company. The call will take place on Tuesday, November 7, 2023, before the market opens. A live webcast will be accessible through Summit’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
Dr. Howard West joins Summit Therapeutics as Vice President of Clinical Development focused on lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
Summit Therapeutics Inc.
Nasdaq:SMMT
SMMT Rankings
SMMT Stock Data
About SMMT
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.